Combination Therapy Extends Survival in Patients with Severe Heart Disease
A groundbreaking study shows that combining valve replacement with targeted drug therapy significantly improves survival in patients with severe heart conditions, including aortic stenosis and cardiac amyloidosis.
Recent research conducted by an international consortium led by MedUni Vienna and University College London has revealed promising advancements in treating severe heart conditions, particularly in patients suffering from both aortic stenosis and cardiac amyloidosis. Traditionally, treatments focused solely on mechanical interventions such as valve replacement, leaving the amyloid deposits in the heart muscle often untreated. However, the new study demonstrates that a combined approach—integrating aortic valve replacement with targeted drug therapy for amyloidosis—significantly improves patient survival rates.
The study analyzed data from 226 patients across ten countries, all diagnosed with both aortic stenosis and cardiac amyloidosis. Aortic stenosis involves the narrowing of the heart valve, obstructing blood flow from the heart's left ventricle into the circulation. Cardiac amyloidosis occurs when misfolded proteins deposit in the heart tissue, impairing its function. Both conditions predominantly affect older adults and frequently coexist.
Importantly, the research shows that patients receiving both valve replacement and tafamidis, a drug used to treat amyloidosis, had notably better survival outcomes. In fact, those who underwent both treatments displayed long-term survival rates similar to patients with aortic stenosis alone without amyloidosis. This underscores the importance of comprehensive treatment strategies.
The findings advocate for routine screening for amyloidosis in patients with severe aortic stenosis. Recognizing the co-occurrence enables healthcare providers to administer targeted therapies that can prolong life and improve quality of life. Early detection and combined treatment are crucial in managing these complex, age-related cardiac diseases.
Overall, this research highlights the potential to change clinical practice by emphasizing the importance of diagnosing and treating both conditions concurrently, paving the way for better patient outcomes in severe heart disease cases.
Source: https://medicalxpress.com/news/2025-06-combination-therapy-prolong-life-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Saliva Testing Equates to Blood Tests for Managing Epilepsy with Keto Diet
A groundbreaking saliva test now matches blood tests in accurately monitoring ketone levels for epilepsy management, offering a painless alternative for children and adults on the ketogenic diet.
Comprehensive Overview of Cystic Fibrosis: Symptoms, Causes, and Modern Treatments
Explore the latest insights into cystic fibrosis, including symptoms, causes, and breakthrough treatments that improve quality of life for those affected.
Blood Sugar Responses to Carbohydrates Reveal Metabolic Health Subtypes
New research reveals that individual blood sugar responses to carbohydrates can indicate different metabolic health subtypes, paving the way for personalized diabetes prevention strategies.
New Research Questions Effectiveness of Tramadol for Chronic Pain Management
A new analysis reveals that tramadol offers minimal pain relief for chronic pain conditions and poses significant health risks, prompting calls for reduced use and alternative treatments.